דיפרילין  3.75 מג ישראל - עברית - Ministry of Health

דיפרילין 3.75 מג

medison pharma ltd - triptorelin as acetate - אבקה וממס להכנת תרחיף להזרקה - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - prostate cancer: treatment of prostate cancer with metastases. patients who have not previously received hormone therapy show a more marked response to the treatment and respond more frequently if the patient has not previously receieved another hormone treatment. precocious puberty: (before 8 years in girls and 10 years in boys). genital and extragenital endometriosis (stage i to stage iv): treatment should not be administered for more than 6 months. it is not recomended to start a second treatment course with triptorelin or another gnrh analogue. treatment of uterine fibromyomas prior to surgery: associated with anaemia ( haemoglobin less than, or equal to 8 g/dl). when a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery. the treatment duration is restricted to 3 months. female infertility: supplementary treatment in combination with gonadotrophins (hmg, fsh, hcg) to induce ovulation with a view to in vitro fertilisa

דקפפטיל סי.אר. ישראל - עברית - Ministry of Health

דקפפטיל סי.אר.

ferring pharmaceuticals ltd - triptorelin as acetate - powder for suspension for injection - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - lowering sexual hormones, prostate cancer, endomedtriosis, uterus myomatosus, fertility treatment ivf. central precocious puberty.

דיפרלין 0.1 מג ישראל - עברית - Ministry of Health

דיפרלין 0.1 מג

medison pharma ltd - triptorelin as acetate - אבקה וממס להכנת תמיסה להזרקה - triptorelin as acetate 0.1 mg/vial - triptorelin - triptorelin - female infertility: management of ovarian stimulation in association with the gonadotrophins (hmg, fsh, hcg) in view of in vitro fertilisation and embrio transfer (i.v.f.e.t.) and other assisted conception techniques.

דקפפטיל דפו 11.25 מג ישראל - עברית - Ministry of Health

דקפפטיל דפו 11.25 מג

ferring pharmaceuticals ltd - triptorelin as embonate - suspension for injection - triptorelin as embonate 11.25 mg - triptorelin - triptorelin - prostatic cancer and lowering of sexual hormones.

דקפפטיל דפו 3.75 מג ישראל - עברית - Ministry of Health

דקפפטיל דפו 3.75 מג

ferring pharmaceuticals ltd - triptorelin as embonate - suspension for injection - triptorelin as embonate 3.75 mg ml - triptorelin - triptorelin - lowering of sexual hormones and treatment of advanced prostate cancer. central precocious puberty.

דקפפטיל דפו 22.5 מג  ישראל - עברית - Ministry of Health

דקפפטיל דפו 22.5 מג

ferring pharmaceuticals ltd - triptorelin as embonate - אבקה וממס להכנת תרחיף להזרקה - triptorelin as embonate 22.5 mg - triptorelin

דקפפטיל 0.1 ישראל - עברית - Ministry of Health

דקפפטיל 0.1

ferring pharmaceuticals ltd - triptorelin acetate - תמיסה להזרקה - triptorelin acetate 0.1 mg/ml - triptorelin - triptorelin - precocius puberty, prostatic cancer, endomethriosis, uterus myomatoses and ivf.

דקפפטיל 0.1 ישראל - עברית - Ministry of Health

דקפפטיל 0.1

ferring pharmaceuticals ltd - triptorelin acetate - תמיסה להזרקה - triptorelin acetate 0.1 mg/ml - triptorelin

ביקאלוטמיד אינובמד 150 מג ישראל - עברית - Ministry of Health

ביקאלוטמיד אינובמד 150 מג

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

אנאסטרוזול אינובמד 1 מג ישראל - עברית - Ministry of Health

אנאסטרוזול אינובמד 1 מג

inovamed ltd - anastrozole - טבליות מצופות פילם - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.